{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:37:03Z","timestamp":1793731023819,"version":"4.6.1"},"reference-count":46,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Tyrosine kinase inhibitors (TKIs) have dramatically changed the survival of chronic myeloid leukemia (CML) patients, and treatment-free remission (TFR) has recently emerged as a new goal of CML treatment. The aim of this work was to develop recommendations for TKI discontinuation in Latin America (LA), outside of clinical trials. A working group of CML experts from LA discussed 22 questions regarding TFR and reached a consensus for TFR recommendations in the region. TFR is indicated in patients in first chronic phase, with typical BCR-ABL transcripts, under TKI treatment of a minimum of 5 years, in sustained deep molecular response (DMR; molecular response 4.5 [MR4.5]) for 2 years. Sustained DMR must be demonstrated on at least 4 international reporting scale quantitative polymerase chain reaction (PCR) tests, separated by at least 3 months, in the immediate prior 2 years. After second-line therapy, TFR is indicated in previously intolerant, not resistant, patients. Molecular monitoring is recommended monthly for the first 6 months, every 2 to 3 months from months 7 to 12, and every 3 months during the second year, indefinitely. Treatment should be reintroduced if major molecular response is lost. Monitoring of withdrawal syndrome, glucose levels, and lipid profile is recommended after discontinuation. After TKI reintroduction, molecular monitoring is indicated every 2 to 3 months until MR4.0 achievement; later, every 3 to 6 months. For the TFR attempt, having standardized and reliable BCR-ABL PCR tests is mandatory. These recommendations will be useful for safe discontinuation in daily practice and will benefit patients who wish to stop treatment in emergent regions, in particular, with TKI-related chronic adverse events.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003235","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T21:57:52Z","timestamp":1630015072000},"page":"4855-4863","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":38,"title":["Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel"],"prefix":"10.1182","volume":"5","author":[{"given":"Carolina","family":"Pavlovsky","sequence":"first","affiliation":[{"name":"Fundaci\u00f3n para Combatir la Leucemia (FUNDALEU), Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-4041","authenticated-orcid":false,"given":"Virginia","family":"Abello Polo","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Universitaria de Ciencias de la Salud, Hospital de San Jos\u00e9, Bogot\u00e1, Colombia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-0805","authenticated-orcid":false,"given":"Katia","family":"Pagnano","sequence":"additional","affiliation":[{"name":"Centro de Hematologia e Hemoterapia, University of Campinas, Campinas, S\u00e3o Paulo, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Ines","family":"Varela","sequence":"additional","affiliation":[{"name":"Hospital J. M. Ramos Mejia, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3174-3208","authenticated-orcid":false,"given":"Claudia","family":"Agudelo","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Colsanitas, Bogot\u00e1, Colombia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bianchini","sequence":"additional","affiliation":[{"name":"Centro de Investigaciones Oncol\u00f3gicas\u2013Fundaci\u00f3n C\u00e1ncer (CIO-FUCA), Instituto A. Fleming, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Boquimpani","sequence":"additional","affiliation":[{"name":"HEMORIO and Oncocl\u00ednica, Rio de Janeiro, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7145-2552","authenticated-orcid":false,"given":"Renato","family":"Centrone","sequence":"additional","affiliation":[{"name":"Instituto Hemomed, S\u00e3o Paulo, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1460-801X","authenticated-orcid":false,"given":"Monica","family":"Conchon","sequence":"additional","affiliation":[{"name":"Hospital Santa Marcelina, S\u00e3o Paulo, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Delgado","sequence":"additional","affiliation":[{"name":"Instituto Mexicano del Seguro Social, Instituto Polit\u00e9cnico Nacional, Ciudad de Mexico, Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2122-7277","authenticated-orcid":false,"given":"Vaneuza","family":"Funke","sequence":"additional","affiliation":[{"name":"Universidade Federal do Parana, Curitiva, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Giere","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n para Combatir la Leucemia (FUNDALEU), Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Luise","sequence":"additional","affiliation":[{"name":"National Cancer Institute of Brazil, Rio de Janeiro, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Meillon","sequence":"additional","affiliation":[{"name":"Instituto Mexicano del Seguro Social, Instituto Polit\u00e9cnico Nacional, Ciudad de Mexico, Mexico;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Moiraghi","sequence":"additional","affiliation":[{"name":"Hospital J. M. Ramos Mejia, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6272-2629","authenticated-orcid":false,"given":"Juan Ramon","family":"Navarro","sequence":"additional","affiliation":[{"name":"Hospital Rebagliati, Lima, Per\u00fa;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6894-7589","authenticated-orcid":false,"given":"Lilian","family":"Pilleux","sequence":"additional","affiliation":[{"name":"Hospital de Valdivia, Los R\u00edos, Chile;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Ines","family":"Prado","sequence":"additional","affiliation":[{"name":"Hospital Maciel, Montevideo, Uruguay;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Undurraga","sequence":"additional","affiliation":[{"name":"Hospital del Salvador, Santiago, Chile; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"issue":"11","key":"2021112416214120900_B1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med."},{"issue":"10","key":"2021112416214120900_B2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med."},{"issue":"24","key":"2021112416214120900_B3","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol."},{"issue":"3","key":"2021112416214120900_B4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.clml.2018.12.004","article-title":"Cardiovascular risk and cardiovascular events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"19","author":"Assun\u00e7\u00e3o","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"4","key":"2021112416214120900_B5","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1002\/ajh.23938","article-title":"Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: data from the FDA Adverse Event Reporting System","volume":"90","author":"Cortes","year":"2015","journal-title":"Am J Hematol."},{"issue":"6","key":"2021112416214120900_B6","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood."},{"issue":"5","key":"2021112416214120900_B7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s12185-019-02620-2","article-title":"Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors","volume":"109","author":"Sasaki","year":"2019","journal-title":"Int J Hematol."},{"issue":"11","key":"2021112416214120900_B8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"2021112416214120900_B9","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1007\/s00277-015-2320-4","article-title":"Discontinuation of tyrosine kinase therapy in CML","volume":"94","author":"Mahon","year":"2015","journal-title":"Ann Hematol."},{"issue":"7","key":"2021112416214120900_B10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann Intern Med."},{"issue":"7","key":"2021112416214120900_B11","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia."},{"issue":"2","key":"2021112416214120900_B12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","article-title":"Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study","volume":"107","author":"Takahashi","year":"2018","journal-title":"Int J Hematol."},{"issue":"4","key":"2021112416214120900_B13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood."},{"issue":"5","key":"2021112416214120900_B14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment","volume":"18","author":"Okada","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"6","key":"2021112416214120900_B15","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"2021112416214120900_B16","first-page":"1595","article-title":"Pilot study of imatinib discontinuation in patients with chronic myeloid leukemia with deep molecular response (EDI-PIO) \u2014 evaluation of pioglitazone in treatment-free remission","volume":"130","author":"Pagnano","year":"2017","journal-title":"Blood."},{"key":"2021112416214120900_B17","author":"Pagnano"},{"issue":"4","key":"2021112416214120900_B18","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia."},{"issue":"10","key":"2021112416214120900_B19","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Deninger","year":"2020","journal-title":"J Natl Compr Canc Netw."},{"key":"2021112416214120900_B20","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol."},{"issue":"12","key":"2021112416214120900_B21","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1515\/cclm-2019-1283","article-title":"Programme for Harmonization to the International Scale in Latin America for BCR-ABL1 quantification in CML patients: findings and recommendations","volume":"58","author":"Ruiz","year":"2020","journal-title":"Clin Chem Lab Med."},{"issue":"1","key":"2021112416214120900_B22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bjh.14973","article-title":"How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy","volume":"180","author":"Rea","year":"2018","journal-title":"Br J Haematol."},{"issue":"3","key":"2021112416214120900_B23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol."},{"issue":"7","key":"2021112416214120900_B24","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood."},{"key":"2021112416214120900_B25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/asheducation-2015.1.264","article-title":"What\u2019s different about atypical CML and chronic neutrophilic leukemia?","volume":"2015","author":"Dao","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"5","key":"2021112416214120900_B26","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","article-title":"Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study","volume":"144","author":"Ross","year":"2018","journal-title":"J Cancer Res Clin Oncol."},{"key":"2021112416214120900_B27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2019-124408","article-title":"Prognostication of molecular relapses after dasatinib or nilotinib discontinuation in chronic myeloid leukemia (CML): a FI-LMC STOP 2G-TKI study update","volume":"134","author":"Rea","year":"2019","journal-title":"Blood."},{"key":"2021112416214120900_B28","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1200\/JCO.2019.37.15_suppl.7005","article-title":"ENESTop 192-week results: treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL)","volume":"37","author":"Hughes","year":"2019","journal-title":"J Clin Oncol."},{"issue":"21","key":"2021112416214120900_B29","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1182\/blood.V124.21.4547.4547","article-title":"Attitudes and perceptions of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) toward treatment-free remission (TFR)","volume":"124","author":"Boquimpani","year":"2014","journal-title":"Blood."},{"issue":"6","key":"2021112416214120900_B30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.clml.2018.04.005","article-title":"Considerations for treatment-free remission in patients with chronic myeloid leukemia: a joint patient-physician perspective","volume":"18","author":"Saglio","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2021112416214120900_B31","first-page":"387","article-title":"Cancer patient-centered home care: a new model for health care in oncology","volume":"7","author":"Tralongo","year":"2011","journal-title":"Ther Clin Risk Manag."},{"issue":"5","key":"2021112416214120900_B32","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol."},{"issue":"8","key":"2021112416214120900_B33","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3324\/haematol.2018.205054","article-title":"Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice","volume":"104","author":"Fava","year":"2019","journal-title":"Haematologica."},{"issue":"6","key":"2021112416214120900_B34","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1097\/HS9.0000000000000157","article-title":"Blast crisis of CML after TKI discontinuation in a patient with previous stable deep molecular response: is it safe to stop?","volume":"2","author":"Papalexandri","year":"2018","journal-title":"HemaSphere."},{"issue":"25","key":"2021112416214120900_B35","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","article-title":"Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?","volume":"32","author":"Richter","year":"2014","journal-title":"J Clin Oncol."},{"issue":"7","key":"2021112416214120900_B36","first-page":"873","article-title":"Musculoskeletal pain after stopping tyrosine kinase inhibitor in patients with chronic myeloid leukemia: a questionnaire survey","volume":"57","author":"Katagiri","year":"2016","journal-title":"Rinsho Ketsueki."},{"issue":"23","key":"2021112416214120900_B37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood.V126.23.137.137","article-title":"Osteoarticular pain after discontinuation of tyrosine kinase inhibitors (TKI): a French cohort","volume":"126","author":"Berger","year":"2015","journal-title":"Blood."},{"key":"2021112416214120900_B38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","article-title":"Treatment-free remission in CML: who, how, and why?","volume":"2017","author":"Mahon","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"3","key":"2021112416214120900_B39","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.16083","article-title":"Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome","volume":"187","author":"Berger","year":"2019","journal-title":"Br J Haematol."},{"issue":"5","key":"2021112416214120900_B40","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11899-017-0404-z","article-title":"Chronic myeloid leukemia-the promise of tyrosine kinase inhibitor discontinuation","volume":"12","author":"Narra","year":"2017","journal-title":"Curr Hematol Malig Rep."},{"key":"2021112416214120900_B41","first-page":"S168","article-title":"Impacto financeiro da descontinua\u00e7\u00e3o de imatinibe \u2013 um estudo farmacoecon\u00f4mico","volume":"41","author":"Centrone","year":"2019","journal-title":"Hematol Transfus Cell Ther."},{"issue":"1","key":"2021112416214120900_B42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12902-018-0303-x","article-title":"Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor","volume":"18","author":"G\u00f3mez-S\u00e1mano","year":"2018","journal-title":"BMC Endocr Disord."},{"key":"2021112416214120900_B43","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2019-125368","article-title":"Duration of major molecular response and discontinuation in deep molecular response (MR4.5) were associated with longer treatment-free survival after imatinib discontinuation - results from two prospective Brazilian trials","volume":"134","author":"Pagnano","year":"2019","journal-title":"Blood."},{"issue":"14","key":"2021112416214120900_B44","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/cncr.31411","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group","volume":"124","author":"Rea","year":"2018","journal-title":"Cancer."},{"issue":"11","key":"2021112416214120900_B45","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1089\/thy.2010.0251","article-title":"Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia","volume":"20","author":"Kim","year":"2010","journal-title":"Thyroid."},{"key":"2021112416214120900_B46","first-page":"2","article-title":"Management of atrial fibrillation in patients taking targeted cancer therapies","volume":"3","author":"Asnani","year":"2017","journal-title":"Cardiooncology."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/23\/4855\/1846412\/advancesadv2020003235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/23\/4855\/1846412\/advancesadv2020003235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T16:22:35Z","timestamp":1637770955000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/23\/4855\/476691\/Treatment-free-remission-in-patients-with-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":46,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2021,12,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003235","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]}}}